NL-OMON39699已完成3 期
The effect of glycopyrroniumbromide on nocturnal clozapine induced sialorrhea in psychiatric patients: a randomized, cross-over, double blind, placebo controlled trial with an extended open label phase (QUITSPIT study) - QUITSPIT-study
niversitair Medisch Centrum Utrecht0 个研究点目标入组 33 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99(—)
入选标准
- •-patients using clozapine who are diagnosed with schizophrenia, a schizoaffective disorder or other psychiatric condition meeting DSM-IV criteria;
- •-a clozapine dosage that remained unchanged for one months prior to inclusion;
- •-age between 18 and 65 years;
- •-nocturnal sialorrhea defined as a score > 2 on the PGI-S (Patient Global Impression of Severity Questionnaire)
- •-no change in dosages of specific comedication (clonidine, sulpride, moclobemide) that potentially reduces salivary flow for 16 days prior to inclusion
- •-the patients is able to answer questionnaires during a weekly consultation (by telephone) with the researcher
- •- the patient is willing to give informed consent for participating in the study
- •-the patient is, according to the treating psychiatrist, competent and able to give informed consent for participating in the study.
排除标准
- •-known hypersensitivity to glycopyroniumbromide, sorbic acid or saccharine sodium;
- •-a comorbidity associated with sialorrhea (Parkinsons disease, cerebral palsy);
- •-one of the following comorbidities: inadequately treated constipation, urine retention, bladder obstruction
- •-concurrent use of anticholinergic agents: tricyclic antidepressants or anticholinergics (atropine, ipratropiumbromide, trihexyfenidyl,
- •biperiden, scopolamine, oxybutinine);
- •-concurrent use of medications that potentially interact with glycopyrroniumbromide
- •(potassium chloride retard tablets, digoxine, corticosteroids)
- •-pregnancy or lactation
- •-a history of myasthenia gravis, cardiac arrhythmia, symptomatic coronary insufficiency, glaucoma, pyloris stenosis, paralytic ileus, prostate hypertrophy, renal failure
- •-unable to autonomic medication intake
研究者
相似试验
进行中(未招募)
不适用
The effect of glycopyrroniumbromide oral solution for nocturnal drooling due to the use of clozapineEUCTR2012-002299-15-NLniversitair Medisch Centrum Utrecht
已完成
不适用
The effect of glycopyrroniumbromide oral solution for nocturnal drooling due to the use of clozapine.English: CIS, clozapine-induced-sialorrhea, hypersalivation, droolingNederlands: sialorroe, hypersalivatie, kwijlenNL-OMON26368Mw. Dr. Ingeborg WiltingziekenhuisapothekerUniversitair Medisch Centrum Utrechtziekenhuisapotheek33
尚未招募
不适用
Inhaled glycopyrronium on excessive sialorrhea and droolingSialorrhea, drooling, Parkinson Disease.Speekselvloed, kwijlen, Ziekte van ParkinsonNL-OMON27582Medisch Spectrum Twente, Enschede10
招募中
4 期
Safety and efficacy of mirabegron on nocturia and quality of sleep in Japanese patients with overactive bladder.overactive bladderJPRN-UMIN000012869Fujita Health University100
已完成
不适用
A clinical study on the effect of glycopyrrolate on the maternal blood pressure and vasopressor requirement during cesarean deliveryCTRI/2020/12/029495JSS Medical College and Hospital60
